摘要
目的观察通心络胶囊对急性心肌梗死患者行急诊冠状动脉支架手术中发生无复流的风险及近期预后的影响。方法急性心肌梗死患者120例,随机分为服用通心络组（治疗组,n=48）和未服用通心络组（对照组,n=72）,治疗组术前均连续服用通心络胶囊1周以上（2~4粒,3次/d）,对照组术前均未服用通心络胶囊,按常规方法行急诊支架置人术。观察术中TIMI血流分级,术后校正心肌梗死溶栓试验血流分级帧数（CTFC）,术后心功能等。结果治疗组术中无复流5例（10.4%）,对照组11例（15.3%）,2组比较差异无统计学意义（P〉0.05）。治疗组术后CTFC为（26.7±8.3）帧,对照组为（29.7±7.2）帧,2组比较差异有统计学意义（P〈0.05）术后1周治疗组LVEF为（52.7±8.0）%优于对照组（48.5±8.8）%,治疗组NT-proBNP为（1217±1363）pg/ml低于对照组的（1815±1493）pg/ml（P均〈0.05）。结论术前服用通心络胶囊不能降低急性心肌梗死支架术中无复流的发生率,但仍可以提高冠状动脉向前血流,改善心功能。
Objective To observe the effect of Tongxinluo capsule on acute myocardial infarction underwent emergency coronary scent with risks of no-reflow and short-term prognosis.Methods 120 patients with acute myocardial infarction were randomly divided into taking Tongxinluo group（treatment group,n=48）and without taking Tongxinluo capsule（control group,n=72）,preoperative treatment group were continuously taking Tongxinluo more than I week（2 to 4,3 times a day）,the control group didni taking Tongxinluo capsule by conventional methods underwent emergency stenting.TIMI flow grade intraoperative and postoperative corrected TIMI flow grade test frames（CTFC）,cardiac function and so on.Results Treatment group were with no-reflow in five cases（10.4%）,in the control group of 11 patients（15.3%）,the two groups showed no significant difference（P0.05）.CTFC postoperative in treatment group was（26.7±8.3）frame,the control group was（29.7±7.2）frames,2 groups＇ difference was statistically significant（P0.05）.After one week,LVEF in treatment group was（52.7±8.0）%,is better than the control group with（48.5±8.8）%,NT-proBNP was（1217±1363）pg/ml in treatment group,lower than the control group with（1815±1493）Pg/ml（P0.05）.Conclusion Preoperative to king Tongxinluo capsule cannot reduce stenting in acute myocardial infarction,the incidence of no-reflow,but still can improve coronary blood flow and improve cardiac function.
出处
《疑难病杂志》
CAS
2014年第1期80-82,共3页
Chinese Journal of Difficult and Complicated Cases
关键词
通心络
心肌梗死
急性
经皮冠状动脉介入治疗
无复流
Tongxinluo capsule
Myocardial infarction
acute
Percutaneous coronary intervention
No-reflow
